Goldman Sachs Downgrades Jazz Pharmaceuticals (JAZZ) to Sell

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

September 14, 2020 12:57 AM EDT
Get Alerts JAZZ Hot Sheet
Price: $244.32 -0.62%

Rating Summary:
    33 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE

Goldman Sachs analyst Graig Suvannavejh downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Sell with a price target of $128.00.


For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.


Shares of Jazz Pharmaceuticals closed at $136.80 yesterday.


You May Also Be Interested In





Related Categories

Downgrades, Hot Downgrades